CN113667645A - Canine breast cancer cell line, and establishment method and application thereof - Google Patents
Canine breast cancer cell line, and establishment method and application thereof Download PDFInfo
- Publication number
- CN113667645A CN113667645A CN202110953836.3A CN202110953836A CN113667645A CN 113667645 A CN113667645 A CN 113667645A CN 202110953836 A CN202110953836 A CN 202110953836A CN 113667645 A CN113667645 A CN 113667645A
- Authority
- CN
- China
- Prior art keywords
- breast cancer
- tumor
- cell line
- cells
- canine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000282465 Canis Species 0.000 title claims abstract description 58
- 206010006187 Breast cancer Diseases 0.000 title claims abstract description 45
- 208000026310 Breast neoplasm Diseases 0.000 title claims abstract description 41
- 238000000034 method Methods 0.000 title claims description 6
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 60
- 239000008267 milk Substances 0.000 claims abstract description 16
- 210000004080 milk Anatomy 0.000 claims abstract description 16
- 235000013336 milk Nutrition 0.000 claims abstract description 16
- 206010027476 Metastases Diseases 0.000 claims abstract description 15
- 230000009401 metastasis Effects 0.000 claims abstract description 15
- 238000004321 preservation Methods 0.000 claims abstract description 15
- 210000004072 lung Anatomy 0.000 claims abstract description 12
- 238000000338 in vitro Methods 0.000 claims abstract description 11
- 230000002269 spontaneous effect Effects 0.000 claims abstract description 9
- 238000011081 inoculation Methods 0.000 claims abstract description 8
- 238000009629 microbiological culture Methods 0.000 claims abstract description 4
- 230000005405 multipole Effects 0.000 claims abstract description 3
- 210000004027 cell Anatomy 0.000 claims description 130
- 238000011580 nude mouse model Methods 0.000 claims description 20
- 210000000349 chromosome Anatomy 0.000 claims description 14
- 230000005740 tumor formation Effects 0.000 claims description 13
- 241000699660 Mus musculus Species 0.000 claims description 10
- 201000011510 cancer Diseases 0.000 claims description 10
- 239000002609 medium Substances 0.000 claims description 8
- 241000282472 Canis lupus familiaris Species 0.000 claims description 7
- 238000004113 cell culture Methods 0.000 claims description 7
- 238000002360 preparation method Methods 0.000 claims description 7
- 210000001519 tissue Anatomy 0.000 claims description 7
- 238000005406 washing Methods 0.000 claims description 7
- 101100257359 Caenorhabditis elegans sox-2 gene Proteins 0.000 claims description 6
- 101100257363 Mus musculus Sox2 gene Proteins 0.000 claims description 6
- 229930182555 Penicillin Natural products 0.000 claims description 6
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 claims description 6
- 238000004458 analytical method Methods 0.000 claims description 6
- 238000012258 culturing Methods 0.000 claims description 6
- 229940049954 penicillin Drugs 0.000 claims description 6
- 230000004614 tumor growth Effects 0.000 claims description 6
- 108091003079 Bovine Serum Albumin Proteins 0.000 claims description 5
- 102100031118 Catenin delta-2 Human genes 0.000 claims description 5
- 102000004162 Claudin-1 Human genes 0.000 claims description 5
- 108090000600 Claudin-1 Proteins 0.000 claims description 5
- 102000004142 Trypsin Human genes 0.000 claims description 5
- 108090000631 Trypsin Proteins 0.000 claims description 5
- 108010031971 delta catenin Proteins 0.000 claims description 5
- 238000010166 immunofluorescence Methods 0.000 claims description 5
- 238000000926 separation method Methods 0.000 claims description 5
- 239000012588 trypsin Substances 0.000 claims description 5
- 210000004881 tumor cell Anatomy 0.000 claims description 5
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 claims description 4
- QTENRWWVYAAPBI-YZTFXSNBSA-N Streptomycin sulfate Chemical compound OS(O)(=O)=O.OS(O)(=O)=O.OS(O)(=O)=O.CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@H]1[C@H](N=C(N)N)[C@@H](O)[C@H](N=C(N)N)[C@@H](O)[C@@H]1O.CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@H]1[C@H](N=C(N)N)[C@@H](O)[C@H](N=C(N)N)[C@@H](O)[C@@H]1O QTENRWWVYAAPBI-YZTFXSNBSA-N 0.000 claims description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 claims description 4
- 102000029816 Collagenase Human genes 0.000 claims description 3
- 108060005980 Collagenase Proteins 0.000 claims description 3
- 241000124008 Mammalia Species 0.000 claims description 3
- 229960002424 collagenase Drugs 0.000 claims description 3
- 238000005138 cryopreservation Methods 0.000 claims description 3
- 230000007773 growth pattern Effects 0.000 claims description 3
- 238000002955 isolation Methods 0.000 claims description 3
- 238000011084 recovery Methods 0.000 claims description 3
- 238000003556 assay Methods 0.000 claims description 2
- 239000000090 biomarker Substances 0.000 claims description 2
- 230000001413 cellular effect Effects 0.000 claims description 2
- 238000005520 cutting process Methods 0.000 claims description 2
- 210000000981 epithelium Anatomy 0.000 claims description 2
- 239000012894 fetal calf serum Substances 0.000 claims description 2
- 230000004927 fusion Effects 0.000 claims description 2
- 230000002068 genetic effect Effects 0.000 claims description 2
- 230000012010 growth Effects 0.000 claims description 2
- 230000009036 growth inhibition Effects 0.000 claims description 2
- 230000007774 longterm Effects 0.000 claims description 2
- 229960005322 streptomycin Drugs 0.000 claims description 2
- 238000001665 trituration Methods 0.000 claims description 2
- 230000002759 chromosomal effect Effects 0.000 claims 1
- 238000011160 research Methods 0.000 abstract description 16
- 230000007246 mechanism Effects 0.000 abstract description 7
- 238000011161 development Methods 0.000 abstract description 4
- 239000003814 drug Substances 0.000 abstract description 4
- 229940079593 drug Drugs 0.000 abstract description 3
- 239000003596 drug target Substances 0.000 abstract description 3
- 238000001727 in vivo Methods 0.000 abstract description 3
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 13
- 239000002953 phosphate buffered saline Substances 0.000 description 13
- 208000003721 Triple Negative Breast Neoplasms Diseases 0.000 description 10
- 208000022679 triple-negative breast carcinoma Diseases 0.000 description 10
- 241000699670 Mus sp. Species 0.000 description 9
- 239000006285 cell suspension Substances 0.000 description 9
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 238000007664 blowing Methods 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 4
- 101100221122 Caenorhabditis elegans cmt-1 gene Proteins 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 229930040373 Paraformaldehyde Natural products 0.000 description 3
- 238000010009 beating Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 239000012091 fetal bovine serum Substances 0.000 description 3
- 239000000834 fixative Substances 0.000 description 3
- 229920002866 paraformaldehyde Polymers 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 230000003442 weekly effect Effects 0.000 description 3
- XCCHQGIGHCRZOS-KBKZQPOHSA-N (4as,5as,6s,12ar)-1,6,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4,4a,5,5a-tetrahydrotetracene-2-carboxamide Chemical compound C1=CC=C2[C@@](C)(O)[C@@H](C[C@@H]3[C@](C(O)=C(C(N)=O)C(=O)C3)(O)C3=O)C3=C(O)C2=C1O XCCHQGIGHCRZOS-KBKZQPOHSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- 101100298998 Caenorhabditis elegans pbs-3 gene Proteins 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 208000000059 Dyspnea Diseases 0.000 description 2
- 206010013975 Dyspnoeas Diseases 0.000 description 2
- 210000000577 adipose tissue Anatomy 0.000 description 2
- 238000007605 air drying Methods 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 description 2
- 230000004709 cell invasion Effects 0.000 description 2
- 238000011109 contamination Methods 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 230000002500 effect on skin Effects 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- 102000015694 estrogen receptors Human genes 0.000 description 2
- 108010038795 estrogen receptors Proteins 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000009456 molecular mechanism Effects 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000005748 tumor development Effects 0.000 description 2
- 238000012795 verification Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 238000012447 xenograft mouse model Methods 0.000 description 2
- 101100314454 Caenorhabditis elegans tra-1 gene Proteins 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 238000000116 DAPI staining Methods 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 1
- 241000725303 Human immunodeficiency virus Species 0.000 description 1
- -1 Ki-67 Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000204031 Mycoplasma Species 0.000 description 1
- 206010029098 Neoplasm skin Diseases 0.000 description 1
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 238000011888 autopsy Methods 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 239000002771 cell marker Substances 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000005056 compaction Methods 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 210000001703 glandular epithelial cell Anatomy 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000001794 hormone therapy Methods 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000031864 metaphase Effects 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000012120 mounting media Substances 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 230000009826 neoplastic cell growth Effects 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 239000000583 progesterone congener Substances 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000439 tumor marker Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0693—Tumour cells; Cancer cells
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0271—Chimeric vertebrates, e.g. comprising exogenous cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0625—Epidermal cells, skin cells; Cells of the oral mucosa
- C12N5/0631—Mammary cells
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2207/00—Modified animals
- A01K2207/12—Animals modified by administration of exogenous cells
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0331—Animal model for proliferative diseases
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Environmental Sciences (AREA)
- Oncology (AREA)
- Animal Behavior & Ethology (AREA)
- Animal Husbandry (AREA)
- Biodiversity & Conservation Biology (AREA)
- Dermatology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
The invention provides a canine breast cancer cell line, and establishment and application thereof. The dog breast cancer cell line dog milk F17 has the preservation number of CGMCC No.22349 and the preservation date of 2021, 05 and 26 days; the name of the preservation unit is China general microbiological culture Collection center. The cell line cells provided by the invention are characterized by a multipole epithelial morphology, are aggregated into a sheet shape or a cluster shape, are firmly attached to the wall, and are difficult to digest and separate. The cell inoculation tumor forming rate and spontaneous lung metastasis are 100 percent, the kit is suitable for in-vivo and in-vitro experimental research of canine breast cancer, provides a good in-vitro experimental model for tumor occurrence development mechanism research, drug target point research and drug treatment mechanism research, and has important basic research and clinical application values.
Description
Technical Field
The invention belongs to the technical field of microbial animal cell lines, and particularly relates to a canine breast cancer cell line, and establishment and application thereof.
Background
Triple Negative Breast Cancer (TNBC) accounts for approximately 15% of all breast cancer cases and does not express the Progestogen Receptor (PR), the Estrogen Receptor (ER) and the human epidermal growth factor receptor 2(HER 2). Thus, hormone therapy is not beneficial to them. The overall survival rate for TNBC patients was lower than for non-TNBC patients.
Canine breast Cancer (CMT) is one of the most common tumors in uninfected bitches. In the clinic, CMT is the second largest tumor to skin tumors only. Since CMT has similar epidemiological, histological, and clinical features as HBC, about 50% of CMT cases are malignant. CMT has been used as a good model for studying human breast cancer.
At present, the molecular mechanism of the canine breast cancer pathogenesis is not very clear, and no ideal treatment scheme or medicament exists. Cell lines can be used in many mechanistic studies, which provide a good platform for studying cell invasion and metastasis mechanisms. Because the cell sources of the dogs are different, the canceration genes are also different, and each cell line is unique in existence and has specificity in cancer research. The established canine breast cancer cell lines are quite limited at present, and the canine triple negative breast cancer cell lines have not been reported. In addition, the defects of instability, low inoculation tumor rate and the like of the prepared canine breast cancer cell line in the prior art exist, so that the development of a CMT cell line which has stability and can reproduce the clinical characteristics of canine triple negative breast cancer is urgently needed.
Disclosure of Invention
In order to solve the technical problems, the invention provides a canine breast cancer cell line and a tumor-bearing mouse successfully, and provides a cell model and a research tool for researching the pathogenesis of canine breast cancer and the tumor metastasis molecular mechanism. The invention also provides an establishment method of the canine breast cancer cell line capable of stably forming tumors in nude mice.
In order to achieve the purpose, the invention adopts the following technical scheme that:
the canine breast cancer cell line is named as canine milk F17, the preservation number is CGMCC No.22349, and the preservation date is 2021, 05 and 26 days; the name of the preservation unit is China general microbiological culture Collection center (CGMCC), the preservation unit is CGMCC for short, and the address of the preservation unit is No. 3 of Xilu No. 1 of Beijing, Chaoyang.
Preferably, the canine breast cancer cell line, capable of long-term growth and stable passage in vitro, has the following biological and genetic characteristics: (1) the cells are in the shape of a multipole epithelium, are aggregated into a sheet or a cluster, are firmly attached to the wall, and are difficult to digest, separate and contact with growth inhibition loss; (2) the cells are of canine origin, and the number of chromosomes is 78; (3) the cell inoculation tumor formation rate and the spontaneous lung metastasis rate are 100 percent, and the clinical characteristics of the canine breast cancer can be reproduced.
Preferably, the clinical characteristics are that the logarithmic proliferation phase is 2-4 days, and the immunofluorescence Ki-67, SOX-2, DELTA-CATENIN, CLAUDIN-1 are positive; after cell cryopreservation and recovery, the cells grow well and can be continuously passaged.
The preparation method of the canine breast cancer cell line comprises the following steps:
(1) case tumor isolation: aseptically cutting breast tumor tissues of clinical dogs;
(2) primary culture of tumor cells:
grinding and washing tumor tissue with PBS containing 1% penicillin streptomycin solution for 3 times, collecting tumor debris, decomposing with collagenase II, centrifuging, collecting cells, suspending in DMEM/F12 complete medium containing 10% fetal calf serum, adding 1% penicillin streptomycin, and suspending in 5% CO2Culturing in a cell culture box;
(3) establishing a cell line:
when the cell culture reaches 90% fusion, washing with PBS for 3 times, then digesting with 0.25% trypsin, extracting secondary culture from the digested cell, changing into new culture solution to continue culturing, carrying out passage for 1 time every 3d with the seed separation rate of 1:3, carrying out in vitro passage to 50 generations, and detecting and verifying biological indexes.
In the preparation method described above, preferably, the biological indicator measurement includes cell morphology, chromosome analysis, tumor formation rate and growth pattern. After the cells are purified, the cells can stably grow, the cell morphology is uniform, the cell fluorescent staining observation shows that the cancer cell marker is positively expressed and accords with the characteristics of the cancer cells, and the inoculated cells can grow in a mouse body to make the mouse tumor.
In the preparation method, preferably, the cell morphology is that the cancer cells are characterized by a multipolar epithelial morphology, are aggregated into sheets or clusters, are firmly attached to the wall of a culture flask and are difficult to digest and separate, the chromosome number is 78 through chromosome analysis, the tumor formation rate is 100%, and the tumor growth conforms to a Gompertzian index function model.
Use of a canine breast cancer cell line as described above for the preparation of a model for generating cancer in an immunodeficient mammal with a neoplasia rate of 100%.
The use as described above, the immunodeficient mammal producing the cancer model is a nude mouse tumor-bearing model.
As described above, the canine breast cancer cell line was subcutaneously inoculated in nude mice in an amount of 108And (4) cells.
The progeny cells of the canine breast cancer cell line, substantially or completely retained the characteristics of the parent cell.
The invention has the beneficial effects that:
the canine breast cancer cell line provided by the invention can be used for successfully establishing a nude mouse tumor-bearing model.
The invention utilizes clinical canine primary breast cancer to establish a tumor source, performs cell separation and purification culture, adopts an in vitro culture mode to passage, establishes a canine breast cancer cell line, and can successfully establish a nude mouse tumor bearing model by utilizing the cell line. The cell line cells of the invention are characterized by a multi-polar epithelial morphology, are aggregated into a sheet shape or a cluster shape, are firmly attached to the wall, and are difficult to digest and separate. The cell inoculation tumor forming rate and spontaneous lung metastasis are 100 percent, the clinical characteristics of the triple negative breast cancer are reproduced, the stability is high, the model is an ideal and reliable research model, the model is suitable for in vivo and in vitro experimental research of the canine triple negative breast cancer, a good in vitro experimental model is provided for tumor occurrence development mechanism research, drug target point research and drug treatment mechanism research, and the model has important basic research and clinical application values.
Drawings
FIG. 1 shows the cell morphology of canine milk F17 under an inverted microscope.
FIG. 2 shows chromosome of canine milk F17 cell line.
FIG. 3 shows a tumor-bearing model of nude mice inoculated subcutaneously with canine milk F17 cells.
FIG. 4 shows tumor-bearing histopathological morphology (HE X400) of nude mice inoculated subcutaneously with canine milk F17 cells.
FIG. 5 shows the results of immunofluorescence (Ki-67, SOX-2, DELTA-CATENIN, CLAUDIN-1) measurements of canine milk F17 cells.
Detailed Description
The following examples are intended to further illustrate the invention but should not be construed as limiting it. Modifications and substitutions may be made thereto without departing from the spirit and scope of the invention.
Unless otherwise specified, the technical means used in the examples are conventional means well known to those skilled in the art, and unless otherwise specified, the reagents used in the present invention are analytically pure or above.
Example 1 establishment of canine breast cancer cell lines
1. Isolation of primary tumors
By surgical resection, a mammary tumor was obtained from a 5-year-old addison dog, clinically and histopathologically diagnosed as Canine Mammary Tumor (CMT): with firm, thickened and painful clinical manifestations. After surgical extraction, tumor specimens were rapidly soaked with Phosphate Buffered Saline (PBS) and penicillin streptomycin solution (Gibco, usa).
2. Primary culture of tumor cells
The tumor tissue obtained above was washed 3 times by trituration with PBS containing 1% penicillin streptomycin solution (Gibco, USA). Then, the tumor fragments were collected in a 15 ml centrifuge tube, and 0.2% collagenase II (Sigma, V900892) was added to a tissue volume of 3-4 times at 37 ℃ for 2 hours in a shaker containing 5% carbon dioxide, centrifuged at room temperature for 5 minutes at 1000rpm, the cells were collected, resuspended in 10% fetal bovine serum in DMEM/F12 complete medium (Gibco, USA), 1% penicillin, the cell suspension was added to a 25cm square flask (Corning, USA), and 5% CO was added at 37 ℃ to obtain a cell suspension2Cultured in a cell culture box. Cells were observed daily with a microscope.
3. Establishing a cell line:
when the cell culture reached 90% confluence, the cells were washed 3 times with PBS and then treated with 2ml of complete medium containing 0.25% trypsin (HyClone, USA) and 0.02% EDTA. Extracting secondary culture from digested cells, and replacing with new 25cm2In bottle, concentration is 1x105cells/ml, complete medium resuspended in DMEM/F12 containing 15% fetal bovine serum. Continuously culturing, carrying out passage 1 time every 3d, and the seed separation rate is 1: 3. The epithelial cells can be purified by utilizing the characteristic that the adherence speed of the fibroblasts is obviously higher than that of the epithelial cells. The cells primarily purified by differential adherence method are normally digested to prepare single cell suspension. The cell concentration was calculated on a cell counting plate. The cell concentration was adjusted to 10 cells per 100. mu.L with complete medium, mixed well and added well to a 96-well plate at 100. mu.L/well. And replacing the fresh culture medium every 3d, and culturing for 10-14d to show that cell colonies can grow out of a plurality of holes, namely the purified canine breast cancer cell line which is marked as canine milk F17.
Experimental observation and verification are carried out, and the purified cells shown in figure 1 are obtained by multiple times of digestion passage purification. By karyotyping, the chromosomes of the cell nucleus were extracted and observed under a microscope as shown in FIG. 2. The separated and purified cells are inoculated subcutaneously into nude mice, and all the inoculated mice form tumors, and the tumor formation rate is 100 percent, as shown in figure 3. And (3) staining the tumor-bearing mouse tumor by HE (human immunodeficiency virus) section, and observing the conditions of the breast pad tumor and the lung metastasis section, wherein A is a spontaneous lung metastasis tumor HE section of a nude mouse, and B is a breast tumor-bearing HE section of the nude mouse, as shown in figure 4. The results show that the mammary tumor model can be successfully replicated and spontaneous lung metastasis can occur when the canine F17 cells are inoculated subcutaneously into nude mice, and the success rate is 100%. The purified cells were subjected to cellular immunofluorescence assay, and the expression of tumor marker proteins such as Ki-67, SOX-2, DELTA-CATENIN, CLAUDIN-1, etc. was observed, as shown in FIG. 5. Specifically, the method comprises the following steps: cell morphology: the cancer cells are characterized by a multi-polar epithelial form, are aggregated into a sheet or cluster, are firmly attached to the wall of the culture bottle, and are difficult to digest and separate.
Chromosome analysis: 100 metaphase cells with well dispersed chromosomes were selected for chromosome analysis. After the cells grow to 90%, digesting the cells conventionally, centrifuging and collecting the cells, adding 8mL of 0.075mol/L KCl solution preheated at 37 ℃, lightly blowing and beating the cell clusters by using a suction tube, uniformly mixing, placing the cell clusters in a preheated water bath box at 37 ℃ for hypotonic treatment for 25min, adding 1mL of newly configured fixative (methanol: glacial acetic acid ═ 3:1), carefully blowing and beating by using the suction tube, uniformly mixing, centrifuging at 1000r/min for 8min, removing the supernatant, adding 8mL of fixative, blowing and beating the cell clusters to prepare a cell suspension, and then fixing at room temperature for 20 min. Centrifuging at 1000r/min for 8min, discarding the supernatant, and repeating the fixation once. Discarding the supernatant, adding several drops of newly prepared fixative according to the number of cells, and blowing to make the cells into suspension. Sucking a small amount of cell suspension, dropping 2-3 drops on a glass slide soaked by ice water, blowing away and air-drying. And (3) placing the specimen in Giemsa dye liquor, dyeing for 8min, washing with water to remove loose color, and air-drying. The results show that the chromosome number is 78, which is consistent with the chromosome number of dog cells, and the isolated cells are derived from dogs.
Tumor formation rate and growth pattern: the tumor formation rate is 100%, and the tumor growth conforms to a Gompertzian exponential function model. When the tumor of the mouse grows to 2cm3After peace, mice are examined by means of autopsy, the tumor metastasis condition is examined, multiple metastasis foci can be seen in the lung of the mice, and the spontaneous lung metastasis rate is 100%. The exponential proliferation phase of the canine milk F17 cell line was on days 2-4.
Biological characteristics of the canine milk F17 cell line: dividing the cultured cells into 2 groups, each group comprises 3 cell slide, discarding the culture solution, washing with PBS once, fixing 4% paraformaldehyde at room temperature for 10min, washing with PBS 3 times, penetrating membrane with 1% Triton X-100 for 10min, washing with PBS 3 times, and sealing with goat serum for 40 min. One group is added with monoclonal antibody SOX-2 (diluted by 1: 100), the other group is added with Ki-67 monoclonal antibody (diluted by 1: 100), the mixture is incubated overnight at 4 ℃, PBS is washed for 3 times, the two groups are respectively added with FITC marked goat anti-mouse IgG (diluted by 1: 100), the mixture is incubated for 1h at room temperature in dark, PBS is washed for 3 times, DAPI staining is carried out for 10min, PBS is washed for 3 times, mounting medium is mounted, and observation and photographing are carried out under a laser confocal microscope. The results of cell immunofluorescence detection of Ki-67, SOX-2, DELTA-CATENIN, and CLAUDIN-1 protein expression are shown in FIG. 5.
4. Freezing and recovering cells: after cell cryopreservation and recovery, the cells grow well and can be continuously passaged. And (3) detecting microbial contamination: the cells are free of bacterial, fungal or mycoplasma contamination.
5. Cell counting: and wiping the counting plate and the cover plate and covering the counting plate with the cover plate. After digesting the cells conventionally, sucking a little of the cell suspension, dripping the cell suspension on the edge of the cover slip to enable the suspension to fill the space between the cover slip and the counting plate, standing for 3min, paying attention to no air bubbles below the cover slip, and enabling the suspension not to flow into a side groove. The total number of cells in the four large grids of the plate is counted, and the line pressing cells are counted only on the left side and the upper side. Then, calculating according to the formula: cell number/mL-total of four large cells/4 × 104。
The obtained cell line is named as a canine breast cancer cell line and is recorded as canine milk F17, and is preserved in China general microbiological culture Collection center (CGMCC) at 26.05.18 years, the preservation unit is abbreviated as CGMCC, the preservation number is CGMCC No.22349, and the preservation unit address is No. 3 of Beijing Kogyang district Beichen West Lu No. 1.
Example 2 Balb/SCID nude mouse model of canine mammary cancer
In order to obtain a good mouse xenograft model, 10 obtained after cell counting in example 1 was used8Individual canine milk F17 cell suspensions (resuspended in 0.2ml PBS) were subcutaneously inoculated into left mammary fat pads of 10 5-week-old female Balb/SCID nude mice (purchased from the center of the beijing vintonia test animal). Mice were observed weekly for tumor development. When tumors were found, the length and width of the tumors were monitored weekly with calipers, for example as shown in fig. 3, for 8 weeks. Mice were sacrificed when they developed dyspnea, weakness, or no obvious tumor. Tumors and organs were collected and histopathologically examined in 4% paraformaldehyde (pH 7.4). All the items are completed according to the 'instruction for nursing and using experimental animals'. The result shows that the tumor formation rate of the CMT-1 cell line nude mouse inoculated subcutaneously is 100 percent, the nude mouse invades and infiltrates subcutaneous and dermal layers, and deep layers of tumor are necrotized. After 4 weeks, spontaneous lung metastasis rate was 100%, and histopathological examination confirmed metastatic adenocarcinoma. The tumor growth curve of the transplanted tumor model conforms to a Gompertz function model and grows in a logarithmic mode after a latency period.
The specific operation is as follows:
1. and (3) conventional cell culture:
when the CMT-1 culture reached 90% confluency, it was washed 3 times with PBS, then the cells were digested with 0.25% trypsin (HyClone, USA) for 5min, the digestion was stopped by adding complete medium containing 15% serum, centrifuged at 1000r/min for 5min, the cells were collected, the supernatant was discarded, fresh medium was added, and the blown-down cells were replaced with new 25cm cells2In bottle, concentration is 1x105cells/ml. Denoted CMT-1. And (5) carrying out 1 passage every 3d, wherein the seed separation rate is 1: 3.
Establishing a Balb/SCID nude mouse tumor-bearing model:
to obtain a good mouse xenograft model, cells were cultured to 90%, digested with 0.25% trypsin for 5min, digested by adding complete medium containing 15% fetal bovine serum 15%, centrifuged at 1000r/min for 5min, cells were collected and counted at 108Individual canine milk F17 cell suspensions (resuspended in 0.2ml PBS) were each subcutaneously inoculated into the left mammary fat pad of 10 5-week-old female Balb/SCID nude mice. Mice were observed weekly for tumor development. Mice were sacrificed when they developed dyspnea, weakness, or no obvious tumor. Tumors and organs were collected and histopathologically examined in 4% paraformaldehyde (pH 7.4).
Experimental observation and verification are carried out, and the tumor-bearing mice have the following characteristics:
the tumor formation rate is as follows: the dog milk F17 cells are inoculated to Balb/SCID nude mice for 100 percent tumorigenesis, and the tumor growth accords with a Gompertzian index function model.
Tumor formation time: subcutaneous lumps at the original injected cells were observed one week after inoculation of canine milk F17 cells, and had a hard and pink texture.
Tumor growth conditions: the exponential proliferation phase is at weeks 2-5.
3. Tumor and cancer metastasis in tumor-bearing mice:
tumor cells infiltrating into subcutaneous and dermal layers of the breast inoculation part can be seen, and the deep layer of the tumor is necrotic. Obvious glandular epithelial cell invasion, sheet distribution, space occupation, compaction and central necrosis of a large-area tumor cell infiltration area can be seen in lung tissues. Therefore, the filial cells of the canine breast cancer cell line basically or completely retain the characteristics of the parent cells and have higher stability. The in-situ inoculation tumor formation rate and the spontaneous lung metastasis rate are 100 percent, the clinical characteristics of the triple negative breast cancer are reproduced, the model is an ideal and reliable research model, is suitable for in-vitro and in-vivo research on the canine triple negative breast cancer, and can provide a good in-vitro test model for the research on tumor occurrence development mechanism, drug target point and drug treatment mechanism.
Claims (9)
1. The canine breast cancer cell line is characterized in that the canine breast cancer cell line is canine milk F17 with the preservation number of CGMCC No.22349 and the preservation date of 2021, 05 and 26 days; the name of the preservation unit is China general microbiological culture Collection center, and the address of the preservation unit is No. 3 Xilu No. 1 Beijing.
2. The canine breast cancer cell line of claim 1, wherein the canine breast cancer cell line is capable of long-term growth and stable passage in vitro, and has biological and genetic characteristics of: (1) the cells are in the shape of a multipole epithelium, are aggregated into a sheet or a cluster, are firmly attached to the wall, and are difficult to digest, separate and contact with growth inhibition loss; (2) the cells are of canine origin, and the number of chromosomes is 78; (3) the cell inoculation tumor formation rate and the spontaneous lung metastasis rate are 100 percent, and the clinical characteristics of the canine breast cancer can be reproduced.
3. The canine breast cancer cell line of claim 2, wherein the clinical profile is log-proliferative phase for 2-4 days, positive for immunofluorescence Ki-67, SOX-2, DELTA-CATENIN, CLAUDIN-1; after cell cryopreservation and recovery, the cells grow well and can be continuously passaged.
4. A preparation method of a canine breast cancer cell line comprises the following steps:
(1) case tumor isolation: aseptically cutting breast tumor tissues of clinical dogs;
(2) primary culture of tumor cells:
tumor tissue was washed 3 times by trituration with PBS containing 1% penicillin streptomycin solution, and then, the tumor was treatedCollecting debris, decomposing with collagenase II, centrifuging, collecting cells, suspending in DMEM/F12 complete medium containing 10% fetal calf serum, adding 1% streptomycin, and suspending the cells in 5% CO2Culturing in a cell culture box;
(3) establishing a cell line:
when the cell culture reaches 90% fusion, washing with PBS for 3 times, then digesting with 0.25% trypsin, extracting secondary culture from the digested cell, changing into new culture solution to continue culturing, carrying out passage for 1 time every 3d with the seed separation rate of 1:3, carrying out in vitro passage to 50 generations, and detecting and verifying biological indexes.
5. The method of claim 4, wherein the biological marker assay comprises cellular morphology, chromosomal analysis, tumor formation rate, and growth pattern.
6. The preparation method of claim 5, wherein the cell morphology is that the cancer cells are characterized by a multipolar epithelial morphology, are aggregated into a sheet or cluster shape, are firmly attached to the wall of a culture flask and are difficult to digest and separate, the chromosome analysis shows that the chromosome number is 78, the tumor formation rate is 100%, and the tumor growth conforms to a Gompertzian index function model.
7. Use of a canine breast cancer cell line of any one of claims 1-3 in the preparation of a model for generating cancer in an immunodeficient mammal.
8. The use of claim 7, wherein the cancer model is a nude mouse tumor-bearing model.
9. The use of claim 8, wherein the canine breast cancer cell line is subcutaneously inoculated in nude mice in an amount of 108And (4) cells.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110953836.3A CN113667645B (en) | 2021-08-19 | 2021-08-19 | Canine breast cancer cell line, and establishment method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110953836.3A CN113667645B (en) | 2021-08-19 | 2021-08-19 | Canine breast cancer cell line, and establishment method and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN113667645A true CN113667645A (en) | 2021-11-19 |
| CN113667645B CN113667645B (en) | 2023-04-28 |
Family
ID=78543848
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110953836.3A Active CN113667645B (en) | 2021-08-19 | 2021-08-19 | Canine breast cancer cell line, and establishment method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113667645B (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113980904A (en) * | 2021-11-25 | 2022-01-28 | 华中农业大学 | Canine inflammatory breast cancer cell line and application thereof |
| CN114015655A (en) * | 2021-12-09 | 2022-02-08 | 北京和合医学诊断技术股份有限公司 | HBRCA-959 cell line and culture method and application thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030166026A1 (en) * | 2002-01-09 | 2003-09-04 | Lynx Therapeutics, Inc. | Identification of specific biomarkers for breast cancer cells |
| CN1490403A (en) * | 2003-08-25 | 2004-04-21 | 复旦大学附属肿瘤医院 | Human inflammatory mammary cancer cell lines and its establishment |
-
2021
- 2021-08-19 CN CN202110953836.3A patent/CN113667645B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030166026A1 (en) * | 2002-01-09 | 2003-09-04 | Lynx Therapeutics, Inc. | Identification of specific biomarkers for breast cancer cells |
| CN1490403A (en) * | 2003-08-25 | 2004-04-21 | 复旦大学附属肿瘤医院 | Human inflammatory mammary cancer cell lines and its establishment |
Non-Patent Citations (1)
| Title |
|---|
| HONG ZHANG等: "Establishment and characterization of a new triple-negative canine mammary cancer cell line", 《TISSUE CELL》 * |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113980904A (en) * | 2021-11-25 | 2022-01-28 | 华中农业大学 | Canine inflammatory breast cancer cell line and application thereof |
| CN113980904B (en) * | 2021-11-25 | 2023-11-28 | 华中农业大学 | Canine inflammatory breast cancer cell line and application thereof |
| CN114015655A (en) * | 2021-12-09 | 2022-02-08 | 北京和合医学诊断技术股份有限公司 | HBRCA-959 cell line and culture method and application thereof |
| CN114015655B (en) * | 2021-12-09 | 2023-09-05 | 北京和合医学诊断技术股份有限公司 | HBRCA-959 cell line and culture method and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN113667645B (en) | 2023-04-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101942413B (en) | Birth defect cell bank and construction method thereof | |
| Paraskeva et al. | The isolation and characterization of colorectal epithelial cell lines at different stages in malignant transformation from familial polyposis coli patients | |
| Hu et al. | Biologic properties of three newly established human esophageal carcinoma cell lines | |
| CN113667645A (en) | Canine breast cancer cell line, and establishment method and application thereof | |
| CN109893541B (en) | Application of exosome derived from menstrual blood stem cells in preparation of medicine for treating intrauterine adhesion | |
| CN106801032B (en) | Construction method of human amniotic epithelial stem cell bank | |
| EP0911389A2 (en) | Epithelial cell cultures for in vitro testing | |
| CN112430567B (en) | Culture method and application of urine-derived renal stem cells | |
| CN109609460B (en) | A kind of human glioma cell line and its method for building up and application | |
| CN104399125B (en) | The method that epidermal stem cells breaks up to sweat gland sample epithelial cell | |
| CN113293133B (en) | Human breast malignant phylliform tumor cell strain and application thereof | |
| CN114717190B (en) | Human breast malignant phylliform tumor cell line BPT0713 and application thereof | |
| CN111593026A (en) | Fluorescence-labeled human triple-negative breast cancer bone metastasis cell line | |
| CN107177551B (en) | Human intrahepatic bile duct cancer cell line with high tumor forming capability and application thereof | |
| CN105647869B (en) | Human lung adenocarcinoma cell strain HA1221 and establishment method thereof | |
| CN105062973B (en) | One plant carries HPV feminine gender penis squamous cell carcinomas system that TP53 is mutated and application thereof | |
| CN110499290B (en) | Human Ewing sarcoma cell line | |
| CN112210538A (en) | Human esophageal squamous carcinoma cell line NCCE1, and establishment method and application thereof | |
| CN108451981B (en) | Use skin mesenchymal stem cells treatment system sclerosis | |
| CN108070560A (en) | A kind of isolation and culture method of the primary stomach cancer cell of people | |
| CN113817777B (en) | Congenital giant black nevus benign tumor cell line from human and construction method thereof | |
| CN113234678B (en) | Human small cell lung cancer cell strain with combined drug resistance to etoposide and carboplatin as well as establishment method and application thereof | |
| CN113801849B (en) | Human breast benign phylliform tumor cell strain BPT-0526 and application thereof | |
| CN108841786A (en) | The amnion-derived mescenchymal stem cell preprocess method of people and its application | |
| CN100408676C (en) | Establishing and application of scale cancer cell line of purify species New Zealand mice oral cavaty and palatal surface parts |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |